Absorbed dose estimates for 131i-labelled monoclonal antibody therapy in patients with intraperitoneal pseudomyxoma

Nuclear Medicine Communications

Volumn 21, Issue 4, 2000, Pages 355-360

  Laitinen, J O ^a   Tenhunen, M ^a   Kairemo, K J ^b  

^a Varian Medical Systems Finland   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

B72.3 ANTIBODY; CANCER ANTIBODY; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

APPENDIX TUMOR; ARTICLE; BIOLOGICAL MODEL; FEMALE; HUMAN; METABOLISM; OVARY TUMOR; PERITONEUM PSEUDOMYXOMA; PERITONEUM TUMOR; RADIATION DOSE; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; APPENDICEAL NEOPLASMS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PSEUDOMYXOMA PERITONEI; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; TISSUE DISTRIBUTION;

EID: 0034167694     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200004000-00010     Document Type: Review

References (27)

1. Wertheim I, Fleischhacker D, McLachlin CM, Rice LW, Berkowitz RS, Goff BA. Pseudomyxoma peritonei: A review of 23 cases. Obstet Gynecol 1994; 84: 17-21.
2. Sugarbaker PH. Surgical treatment of peritoneal carcinomatosis: 1988 Du Pont lecture. Can J Surg 1989; 32: 164-170.
3. Kairemo KJA. Radioimmunotherapy of solid cancers: A review. Acta Oncol 1996; 35: 343-355.
4. Roselli M, Hitchcock CL, Molinolo A et al. Autoradiographic evaluation of monoclonal antibody B72.3 distribution in tumor and lymph nodes of adenocarcinoma patients. Anticancer Res 1995; 15: 975-984.
5. Kairemo KJA, Jekunen AP, Bondestam S, Korppi-Tommola ET, Savolainen S, Paavonen T. Detection of pseudomyxoma peritonei by radioimmunohistochemistry and radioimmunoscintigraphy. Cancer Biother Radiopharm 1996; 11: 325-334.
6. Watson EE, Stabin MG, Siegel JA. MIRD formulation. Med Phys 1993; 20: 511-514.
7. Sgouros G, Barest G, Thekkumthala J et al. Treatment planning for internal radionuclide therapy: Three-dimensional dosimetry for nonuniformly distributed radionuclides. J Nucl Med 1990; 31: 1884-1891.
8. Sgouros G, Chiu S, Pentlow KS et al. Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med 1993; 34: 1595-1601.
9. Giap HB, Macey DJ, Bayouth JE, Boyer AL. Validation of a dose-point kernel convolution technique for internal dosimetry. Phys Med Biol 1995; 40: 365-381.
10. Giap HB, Macey DJ, Podoloff DA. Development of a SPECT-based three-dimensional treatment planning system for radioimmunotherapy. J Nucl Med 1995; 36: 1885-1894.
11. Erdi AK, Loew M, Yorke E, Erdi Y, Wessels B. Use of the fast Hartley transform for efficient 3D convolution in calculation of radiation dose. In: Proceedings of the 16th Annual IEEE-EMBS Conference. Piscataway, NJ: IEEE, 1994: 639-406.
12. Laitinen JO, Kairemo KJA, Jekunen AP, Korppi-Tommola T, Tenhunen M. The effect of three dimensional activity distribution on the dose planning of radioimmunotherapy for patients with advanced intraperitoneal pseudomyxoma. Cancer 1997; 80(suppl.): 2545-2552.
13. Laitinen J, Alakuijala J, Helminen H, Sallinen S, Tenhunen M, Kairemo K. SPECT-based radioimmunotherapy planning system. In: Proceedings of IEEE Engineering in Medicine and Biology 19th Annual Conference. Piscataway, NJ: IEEE, 1997: 781-784.
14. Tagesson M, Ljungberg M, Strand SE. A Monte-Carlo program converting activity distributions to absorbed dose distributions in a radionuclide treatment planning system. Acta Oncol 1996; 35: 367-372.
15. Furhang EE, Chui CS, Sgouros G. A Monte Carlo approach to patient-specific dosimetry. Med Phys 1996; 23: 1523-1529.
16. Picker. Odyssey VP operators guide, Vol. 1. Highland Heights, OH: Picker Ohio Imaging Division, 1995.
17. 2 fragments of monoclonal antibody in humans. Med Phys 1984; 11: 778-783.
18. ICRU 32. Methods of assessment of absorbed dose in clinical use of radionuclides. Washington DC, 1979.
19. Furhang EE, Sgouros G, Chui CS. Radionuclide photon dose kernels for internal emitter dosimetry. Med Phys 1996; 23: 759-764.
20. Boyer AL, Mok EC. Brachytherapy seed dose distribution calculation employing the fast Fourier transform. Med Phys 1986; 13: 525-529.
21. Watson EE, Stabin MG, Davis JL, Eckerman KF. A model of the peritoneal cavity for use in internal dosimetry. J Nucl Med 1989; 30: 2002-2011.
22. Emami B, Lyman J, Brown A et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21: 109-122.
23. Erdi AK, Erdi YE, Yorke ED, Wessels BW. Treatment planning for radio-immunotherapy. Phys Med Biol 1996; 41: 2009-2026.
24. Koral KF, Zasadny KR, Kessler ML et al. CT-SPECT fusion plus conjugate views for determining dosimetry in iodine-131-monoclonal antibody therapy of lymphoma patients. J Nucl Med 1994; 35: 1714-1720.
25. Koral KF, Lin S, Fessler JA, Kaminski MS, Wahl RL. Preliminary results from intensity-based CT-SPECT fusion in I-131 anti-B1 monoclonal-antibody therapy of lymphoma. Cancer 1997; 80(suppl.): 2538-2544.
26. Macey DJ, Grant EJ, Bayouth JE et al. Improved conjugate view quantitation of I-131 by subtraction scatter and septal penetration events with a triple energy window method. Med Phys 1995; 22: 1637-1643.
27. Ljungberg M, King MA, Hademenos GJ, Strand SE. Comparison of four scatter correction methods using Monte Carlo simulated source distributions. J Nucl Med 1994; 35: 143-151.